Loading...

Brilliant Violet 421™ anti-human CD69 Antibody

Pricing & Availability
Clone
FN50 (See other available formats)
Regulatory Status
RUO
Workshop
IV A91
Other Names
Very Early Activation Antigen (VEA), Activation inducer molecule (AIM)
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
FN50_BV421_040311
Human peripheral blood lymphocytes were stimulated with PMA + ionomycin for 6 hours and then stained with CD69 (clone FN50) Brilliant Violet 421™ (filled histogram) or mouse IgG1, κ Brilliant Violet 421™ isotype control (open histogram).
  • FN50_BV421_040311
    Human peripheral blood lymphocytes were stimulated with PMA + ionomycin for 6 hours and then stained with CD69 (clone FN50) Brilliant Violet 421™ (filled histogram) or mouse IgG1, κ Brilliant Violet 421™ isotype control (open histogram).
See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability Save
310929 25 tests 141€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
310930 100 tests 305€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 27-33 kD type II transmembrane protein also known as activation inducer molecule (AIM), very early activation antigen (VEA), and MLR3. It is a member of the C-type lectin family, expressed as a disulfide-linked homodimer. Other members of this receptor family include NKG2, NKR-P1 CD94, and Ly49. CD69 is transiently expressed on activated leukocytes including T cells, thymocytes, B cells, NK cells, neutrophils, and eosinophils. CD69 is constitutively expressed by a subset of medullary mature thymocytes, platelets, mantle B cells, and certain CD4+ T cells in germinal centers of normal lymph nodes. CD69 is involved in early events of lymphocyte, monocyte, and platelet activation, and has a functional role in redirected lysis mediated by activated NK cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections2, immunofluorescence microscopy3, and spatial biology (IBEX)8,9.

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp WB, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Sakkas LI, et al. 1998. Clin. and Diag. Lab. Immunol. 5:430. (IHC)
  3. Kim JR, et al. 2005. BMC Immunol. 6:3. (IF)
  4. Verjans GM, et al. 2007. P. Natl. Acad. Sci. USA 104:3496.
  5. Lu H, et al. 2009. Toxicol Sci. 112:363. (FC) PubMed
  6. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  9. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  2. Sagebiel AF, et al. 2019. Nat Commun. 10:975. PubMed
  3. Lucic B, et al. 2019. Nat Commun. 10:4059. PubMed
  4. Dulberger CL et al. 2017. Immunity. 46(6):1018-1029 . PubMed
  5. Carpenter RS, et al. 2019. Sci Rep. 9:19105. PubMed
  6. Bourges C, et al. 2020. EMBO Mol Med. 12:e12112. PubMed
  7. Cooper GE, et al. 2018. Front Immunol. 9:1671. PubMed
  8. Ge C, et al. 2020. Cell Reports. 29(13):4236-4244.e3.. PubMed
  9. Prete G, et al. 2014. Antimicrob Agents Chemother. 58:6790. PubMed
  10. Policicchio B, et al. 2016. PLoS Pathog. 12: 1005879. PubMed
  11. Pettmann J, et al. 2021. eLife. 10:00. PubMed
  12. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
  13. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  14. Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed
  15. Hara T, et al. 2021. Cancer Cell. 39(6):779-792.e11. PubMed
  16. Garcia EG, et al. 2020. Leukemia. 35:679. PubMed
  17. Nguyen THO, et al. 2021. Immunity. 54:1066. PubMed
  18. Dunn JLM, et al. 2021. Mucosal Immunol. 14:1133. PubMed
  19. Gruijs M, et al. 2021. Int J Mol Sci. 22:. PubMed
  20. Pi J, et al. 2022. J Nanobiotechnology. 20:36. PubMed
  21. NULL, et al. 2022. Cell. 185:916. PubMed
  22. Carnevale J, et al. 2022. Nature. 609:174. PubMed
  23. Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed
  24. Vorkas CK, et al. 2022. J Immunol. 208:1042. PubMed
  25. Gartshteyn Y, et al. 2023. Life Sci Alliance. 6: . PubMed
  26. Labanieh L, et al. 2022. Cell. 185:1745. PubMed
RRID
AB_10933255 (BioLegend Cat. No. 310929)
AB_2561909 (BioLegend Cat. No. 310930)

Antigen Details

Structure
C-type lectin, type II glycoprotein, 28/32 kD
Distribution

Activated T cells, B cells, NK cells, granulocytes, thymocytes, platelets, Langerhans cells

Function
Lymphocyte, monocyte, and platelet activation, NK cell killing
Cell Type
B cells, Granulocytes, Langerhans cells, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Testi R, et al. 1994. Immunol. Today 15:479.

Gene ID
969 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Go To Top Version: 1    Revision Date: 11.30.2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account